The Dova study is for children below 18 years with primary Immune Thrombocytopenia (ITP) who have had an insufficient response to previous treatment. The goal of the study is to see if the study drug, Avatrombopag can safely increase platelet counts and improve symptoms for people with ITP. Avatrombopag is an investigational medication designed to make your body produce more platelets. You may be able to join the study if you are:
- 1 year or older but below 18 years of age
- Diagnosed with primary ITP for at least 6 months.
Other study requirements will apply.
For More InformationContact Us Online
Call (267) 426-6846